Drugs / Stem Cell Transplantation
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03069170 | Jul 2016 → Sep 2020 | multiple sclerosis | Stem Cells Arabia | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02644759 | Feb 2014 → Aug 2017 | type 1 diabetes mellitus | Stem Cells Arabia | Completed | No outcome recorded |
| Phase 1/2 | NCT02641769 | Jan 2014 → Jun 2030 expected | azoospermia | Stem Cells Arabia | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Stem Cell Transplantation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03069170 ↗ |
| Action | Restore | “which all aid in the re-establishment of spermatogenesis” NCT02641769 ↗ |
| Modality | Cell therapy | “purified adult autologous, bone marrow derived, highly specialized, differentiation specific into spermatogonial lineages, and mesenchymal stem cells” NCT02641769 ↗ |
| Route | Other | “injected into the seminiferous tubules and testis” NCT02641769 ↗ |